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Abstract

Nasopharyngeal carcinoma (NPC) is a complex disease caused by a combination of Epstein – Barr virus chronic infection, the environment
and host genes in a multi-step process of carcinogenesis.The identity of genetic factors involved in the development of chronic Epstein – Barr
virus infection and NPC remains elusive, however. Here, we describe a two-phase, population-based, case-control study of Han Chinese
from Guangxi province, where the NPC incidence rate rises to a high of 25 – 50 per 100,000 individuals. Phase I, powered to detect
single gene associations, enrolled 984 subjects to determine feasibility, to develop infrastructure and logistics and to determine error rates
in sample handling. A microsatellite screen of Phase I study participants, genotyped for 319 alleles from 34 microsatellites spanning an
18-megabase region of chromosome 4 (4p15.1-q12), previously implicated by a linkage analysis of familial NPC, found 14 alleles marginally
associated with developing NPC or chronic immunoglobulin A production ( p ¼ 0.001 2 0.03). These associations lost signiﬁcance after
applying a correction for multiple tests. Although the present results await conﬁrmation, the Phase II study population has tripled patient
enrolment and has included environmental covariates, offering the potential to validate this and other genomic regions that inﬂuence the
onset of NPC.
Keywords: nasopharyngeal carcinoma, chromosome 4, microsatellite, association study, Epstein – Barr virus

Introduction
Nasopharyngeal carcinoma (NPC) is a disease with distinct racial
and geographical distributions. In southern China, Taiwan,
Vietnam and the Philippines, the incidence of NPC is 15 – 20 per
100,000 individuals per year, and in some local Chinese regions
bordering the Xijiang River drainage in Guangdong and
Guangxi provinces, the incidence is as high as 25 – 50 per
100,000 individuals.1,2 An intermediate incidence is observed

among the Arab populations of Northern Africa,3 including
Saudi Arabia;4 in the Caribbean; and in the Eskimo populations
of Alaska and Greenland.5 Elsewhere, NPC is rare, with an
incidence of less than 1 per 100,000. In the USA, NPC comprises only 0.2 per cent of all malignancies, with an incidence is
1 per 100,000. The male:female ratio for NPC is usually 2 or
3:1, with an incidence peak between 50 and 59 years of age.6
A link between NPC and Epstein –Barr virus (EBV)
was reported in 1966.7 Ten years later, the presence of
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immunoglobulin (Ig) A antibodies to EBV viral capsid antigens
(EBV/IgA/VCA) was found to serve as a predictive marker for
the development of NPC in Chinese populations.8 More than
95 per cent of adults in all ethnic groups across the world are
healthy carriers of EBV. In high NPC incidence regions, EBV
infection of the nasopharyngeal epithelium induces IgA
antibodies against VCA, suggesting that reactivation of EBV
replication at the mucosal surface precedes the development of
NPC. Consistent with this, approximately 2.5 per cent of
the general population are EBV/IgA/VCA antibody positive.
Of these, less than 3 per cent will develop NPC, while
. 95 per cent of all NPC patients are EBV/IgA/VCA antibody
positive.9 – 14 In addition to EBV infection, case control studies
have indicated a role for environmental factors, including food
preservatives (carcinogenic nitrosamines), salt-preserved ﬁsh and
phorbol esters in herbs and plants that are commonly consumed
among ethnic populations with the highest NPC rates.15,16
Evidence for genetic modulation of NPC risk has accumulated recently. Familial aggregation of NPC has been
observed in China and in other countries.17 – 19 Familial
aggregation of NPC is uncommon in low-risk or nonChinese populations. The proportion of NPC with affected
ﬁrst-degree family history is . 5 per cent in south China,
7.2 per cent in Hong Kong, 6.0 per cent in Yulin and 5.9
per cent in Guangzhou.20 Descendants of south Chinese
immigrants to western countries show progressively lower risk,
but their NPC incidence remains higher than that of the
indigenous population,21 suggesting both environmental and
genetic components to disease susceptibility. Several studies
have shown associations between HLA genes and NPC,22 – 28
and the D6S1624 microsatellite within the HLA class I region
has been associated with NPC.29 Studies comparing age of
NPC onset report conﬂicting results for familial versus
sporadic NPC. In a study comparing 200 probands with and
without NPC-affected ﬁrst-degree relatives from Singapore,
the age of onset was 48 and 49 years, respectively.30 In another
Chinese study, the average age of onset was 35.5 years in 32
Guangdong families with 4 – 5 relatives with NPC compared
with 46.6 years for sporadic cases.20 In a third study, however,
the age of onset decreased from 44.5 years to 40.4 as the
number of NPC-affected relatives increased from one to
four.31 There is, therefore, some suggestion that age of onset
may be lower in families with one or more NPC-affected
ﬁrst-degree relatives.
A genome-wide linkage analysis of 20 NPC families from a
high incidence region in Guangdong identiﬁed a susceptibility
region on the short arm of chromosome 4.32 Two chromosome 4p15.1-q12 markers, D4S405 and D4S3002, yielded
high logarithm of the odds (LOD) scores (. 3.5) by both
parametric and multipoint non-parametric analysis in 70 per
cent of the NPC families studied. A subsequent study of
18 families from Hunan province genotyped a panel of
markers on the short arms of chromosomes 3, 9 and 4 that
included D4S405 and D4S3002 and failed to detect an
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obvious susceptibility locus on 4p15.1-q12.33 A region on
chromosome 3p21.31-21.2 containing a tumour suppressor
gene cluster, however, showed a modest association with NPC
incidence.33
Here, we describe the design of a new case — control study
population recruited for the discovery of genetic factors that
are involved in the development of chronic EBV infection and
in the development of NPC. In a preliminary test to resolve
the discrepancy between the two family-based studies, we
performed a population-based case — control association
analysis of 34 microsatellite markers within 4p15.1-q12
(Figure 1) to determine if speciﬁc alleles within the region: 1)
were associated with a propensity to develop chronic EBV
replication, as evidenced by IgA antibodies against EBV viral
capsid antigen (EBV/IgA/VCA); or 2) were associated with
NPC susceptibility.

Materials and methods
Study design

Enrolment into the study occurred in two collection phases.
The Phase I pilot was powered to detect single gene associations and to determine feasibility for meeting recruitment
goals, accuracy of data collection and sample handling, and to
develop the infrastructure for a large international collaboration. Cases and controls (n ¼ 984) were recruited in 2000
from Wuzhou City and Cangwu County, bordering the
Xijiang River in the Guangxi province of South East China.
An effort was made to enrol triads consisting of a proband, an
unaffected spouse and an adult child or parent. Family triads
were enrolled for haplotype inference and for quality control
assessment. Three clinically described disease categories were
collected: 1) incident or prevalent NPC biopsy-conﬁrmed
(NPCþ) cases (n ¼ 350) who were EBV/IgA/VCA antibody
positive (IgAþ); 2) IgAþ cases (n ¼ 288) who were deﬁned as
EBV/IgA/VCA antibody positive and NPC free at the time of
study enrolment (EBV/IgA/VCA titres were conﬁrmed by
serological testing at the time of study enrolment); 3) IgA2
controls (n ¼ 346). For each case, his or her spouse was tested
for EBV/IgA/VCA antibodies, and the spouse and parent or
adult child were invited to enrol. The IgA2 group consisted of
346 spouses who were IgA2 at the time of study enrolment
(Table 1). A dominant model was selected for power calculations for two reasons: 1) if the true model is additive, there is
little difference in power using either an additive model or a
dominant model for power calculations (data not shown); 2) if,
however, the true model is dominant, a dominant model is the
most powerful. Assuming a dominant genetic model and at
least a 10 per cent allele frequency, this number of NPC, IgAþ,
and IgA2 cases and controls provided . 90 per cent power to
detect associations with an odds ratio (OR) $ 3, at the
p ¼ 0.01 level for a two-tailed test (Table 2).
Phase II enrolment was initiated in 2004 and after the
completion of Phase I collection. The Phase II design is a
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Figure 1. Map of markers for the nasopharyngeal carcinoma susceptibility locus on chromosome 4.28 Thirty-four short tandem repeat
markers distributed across an 18 megabase region were selected between D4S2950 to D4S2916, with intervals of 10 – 3,500 kilobases.
The positional relationship among markers and selected genes are indicated below the map. Asterisks indicate levels of statistical
signiﬁcance: *p , 0.05 and * *p , 0.01.

cross-sectional, case control study: family members were not
recruited. A questionnaire capturing environmental factors,
including occupational, dietary and tobacco exposures, was
administered to each study participant at enrolment (Table 3).
NPC cases were recruited from the Wuzhou Red Cross
Hospital in collaboration with the Cancer Institute of
Wuzhou, Wuzhou City and the Cangwu Institute for
Nasopharyngeal Carcinoma Control and Prevention, Cangwu
County. NPC cases, IgAþ subjects and IgA2 participants were
recruited from cities and villages bordering the Xijiang River.
Power was determined for single gene and gene environment
interactions for participants in each group (Table 2). For
single-gene associations at a 10 per cent allele frequency,
power will range from 83 per cent to . 99 per cent and from
35 per cent to . 99 per cent to detect associations with
an odds ratio (OR) of 1.5–3.0 at p , 0.05 and p , 0.001,
respectively, for the dominant genetic model and a two-sided

signiﬁcance level. For gene-environment interactions, there is
power to detect gene-environment effects for genotype and
exposures with frequencies $ 0.1 for genotype and exposure,
if the main exposure effect and genotype have an OR $ 1 and
an interaction effect of OR $ 3.34
Exclusion criteria for Phases I and II were ethnicity other
than Han Chinese, birth or residency for more than six
months outside of the NPC endemic region or failure to
provide informed consent. Internal review board approval was
obtained from all participating institutions and informed
consent was obtained from each study participant or their
guardian for subjects between 16 and 18 years of age.

Sample and data handling

A total of 10 – 20 ml of blood was collected in acid citrate
dextrose (ACD) vacutainers for serology testing, direct DNA
extraction and for cryopreservation of peripheral blood

Table 1. Characteristics of the Phase I study groups.
NPC positive

NPC negative
EBV/IgA/VCA positive

EBV/IgA/VCA negative

No. study participants

350

288

346

Male/female (%male)

233/117 (67%)

142/146 (49%)

129/217 (59%)

Age*

48 ^ 10 (16 –79)

44 ^ 9 (20 – 77)

47 ^ 10 (18 – 75)

IgA/VCA titre

1:10– 1:640

1:5– 1:80

, 1:5

IgA/EA titre

1:10– :160 (57.4%)

1:5– 1:20 (5%)

, 1:5

Abbreviations: EBV, Epstein – Barr virus; IgA, immunoglobulin A; NPC, nasopharyngeal carcinoma; VCA, viral capsid antigens.
* Age at NPC diagnosis and at study enrolment for IgA serostatus.
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Table 2. Phase I and phase II sample power.
Phase I
Case/control
NPC+ vs IgA+

Phase II
Power

350/288
OR

1024/1009

Case/control

Power

1374/1297

1.5

17%

64%

79%

0.50

2.0

62%

. 99%

. 99%

0.33

3.0

98%

. 99%

. 99%

288/346

1009/1022

1297/1368

0.75

1.5

18%

64%

79%

0.50

2.0

64%

99%

. 99%

0.33

3.0

99%

. 99%

. 99%

NPC+/IgA+ vs IgA2

638/346

OR

Power

0.75

IgA+ vs IgA2
OR

Case/control

All

2033/1022

2671/1368

0.75

1.5

25%

77%

90%

0.50

2.0

78%

. 99%

. 99%

0.33

3.0

. 99%

. 99%

. 99%

Note. Allele frequency ¼ 10 per cent; Type 1 error ¼ 1 per cent.
Power calculated for a 10% allele frequency, dominant genetic model and a p value of # 0.01 for given case and control numbers using a two-tailed test. For example, with the
Phase I cases/controls available, we would discover a genetic association of strength OR ¼ 1.5, only 14% of the time, but a stronger gene (OR ¼ 3.0) would be detected 96%
of the time with available patient numbers.
Abbreviations: IgA, immunoglobulin A; NPC, nasopharyngeal carcinoma.

mononuclear cells (PBMCs). Blood samples were separated
into plasma and PBMCs. Serum was tested at the Wuzhou
Centre for EBV/IgA/VCA antibodies and antibodies to EBV
early antigen by immunoenzymatic assay. The PBMCs were
EBV-transformed to establish lymphoblastoid cell lines (LCLs)
as a renewable DNA source. In addition, 3 cc of whole blood
were preserved in DNA Tris, ethylene diamine tetraacetic acid
and sodium dodecyl sulphate extraction buffer as a back-up
DNA source. Questionnaires capturing demographic,

laboratory and social history were administered at enrolment.
Two individuals entered responses to the questionnaire and
laboratory results into a FileMaker Pro database independently
as a method of capturing data entry errors.

Genomic DNA extraction

DNA was extracted from whole blood or lymphoblastoid cell
lines using the QIAamp DNA blood maxi kit (Qiagen,
Valencia, CA, USA, catalog #51194). More than 80 per cent

Table 3. Phase II study design and non-genetic covariates.
Exposure

EBV/IgA/VCA status
NPC/IgA+

IgA+

IgA2

1024

1009

1022

735/289 (72%)

555/454 (55%)

684/338 (67%)

292 (28.5%)

172 (17.0%)

283 (27.7%)

Wood cooking ﬁres

995 (97.2%)

960 (95.1%)

914 (89.4%)

Occupational exposure to solvents2

78 (07.6%)

31 (03.1%)

87 (08.5%)

Smoking .10 years

531 (51.9%)

408 (40.4%)

372 (36.4%)

No. enrolled1
Male:female (% male)
Consume dried meat

2

2

Abbreviations: EBV, Epstein – Barr virus; IgA, immunoglobulin A; NPC, nasopharyngeal carcinoma; VCA, viral capsid antigens.
Greater than 99 per cent of IgAþ and IgA2 participants and 100 per cent of the NPC cases were born in Guangdong or Guangzhou provinces.
Participants reporting any level exposure.

1
2
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of the genotypes were determined from DNA directly
extracted from whole blood.

Microsatellite genotyping

Microsatellite loci (n ¼ 34) containing 319 alleles were selected
between D4S2950 and D4S2916 (18 megabases [Mb]) on
chromosome 4 (Figure 1). The markers consist of 22 dinucleotide repeats, two trinucleotide repeats and ten tetranucleotide
repeats. The genetic and physical distances between marker pairs
are as follows: mean ¼ 0.51 centimorgans (cM), 562 kilobases
(kb); median ¼ 0.34 cM, 230 kb; and range ¼ 0.00 – 2.79 cM,
11 – 4,185 kb. The primer sequences were obtained from the
University of Santa Cruz Genome Bioinformatics database.35 All
of the forward primers were 50 -tailed with the M13 sequence 50 CACGACGTTGTAAAACGAC-30 . The M13-forward primers were used in combination with an M13 primer that had the
same sequence but was labelled at its 50 end with a ﬂuorescent
reagent from Applied Biosystems (ABI) Foster City, CA, USA
such as 6-FAM, VIC or NED. The latter primer is the sole source
of label and can be used with any M13-forward primer to generate a labelled ampliﬁed allele.36 The polymerase chain reaction
(PCR) ampliﬁcations of individual microsatellite loci were
performed in 10 ml volumes containing 10 mM Tris– HCl (pH
8.3), 50 mM KCl, 2.0 mM MgCl2, 0.2 mM of each dinucleotide
triphosphate, 1 mM labelled M13 primer and reverse primer,
0.07 mM M13-tailed primer (15:1 molar ratio of labelled M13
primer versus a M13-tailed forward primer), 25 ng genomic
DNA, 0.5 U TaqGold DNA polymerase (Applied Biosystems,
Foster City, CA, USA). PCR ampliﬁcation was performed in a
PE Applied Biosystems Model 9700 using 384 high-throughput
format plates. The PCR conditions were a modiﬁed touchdown
PCR procedure: 958C, 10 minutes; two cycles of 958C,
15 seconds; annealing temperature, 30 seconds; 728C,
45 seconds, at annealing temperatures of 608C, 588C, 568C,
548C, 528C; 30 cycles at an annealing temperature of 508C;
728C, 30 minutes. Six PCR products were pooled together for
multiplex loading according to the label colour and marker size.
Samples were diluted appropriately, pooled and then 3 ml of
sample was mixed with 9 ml of formamide containing Liz 350
size standard (ABI). Samples were electrophoresed in a 22 cm
capillary array using POP5 polymer and 3700 running buffer
(ABI) on an ABI Model 3100 Automated DNA Sequencer using
data collection software version 1.0.1 and Genescan Analysis
software version 3.7. Genotyping was performed using Genotyper Version 2.5 and allele sizes were binned using Allelogram
(Carl Manaster, available at http://s92417348.onlinehome.us/
software/allelogram/index.html). For quality control between
plates, DNAs from 22 per cent of subjects were duplicated across
plates. Mendelian errors were tested within the triad families
using the PedChek program.37

Genetic association analyses

Allele frequencies were computed and compared between
cases and controls using Pearson’s x2 test or Fisher’s exact test.
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ORs, 95 per cent conﬁdence intervals (CIs) and p values
were computed for dominant and recessive genetic models
adjusted for age and sex. Logistic regression adjusted for age
and sex was used to compute ORs using SAS PROC
LOGISTIC software (SAS Institute, Cary, NC, USA). ORs
were computed for a dominant model, comparing the combined homozygous and heterozygous genotypes against all
other genotypes. When the allele frequency of the minor allele
was $ 5 per cent, ORs were calculated for the recessive
model, comparing the homozygous genotype against all other
genotypes. Conformance to Hardy–Weinberg equilibrium
expectations was calculated for all loci. Tests for D’ as a
measure of linkage disequilibrium (LD) were conducted for
allele pairs using SAS Genetics software (SAS Institute, Cary,
NC, USA).

Results
The Phase I pilot study enrolled participants from the Cancer
Institute in Wuzhou City and the Cangwu Institute for
Nasopharyngeal Carcinoma Control and Prevention, Cangwu
County in Guangxi province in the autumn of 2000. For
NPC cases, 71.3 per cent of spouses and 81 per cent of adult
children were enrolled. For cases with EBV/IgA/VCA titres
consistent with chronic EBV infection, 72.4 per cent of
spouses and 67.4 per cent of adult children or parents were
enrolled. Complete triad sets were available for 366 NPC
probands. As predicted for this highly endemic NPC region,
71.8 per cent of the NPC cases were male. PBMCs cryopreserved on-site were transported to the Laboratory of Genomic
Diversity-National Cancer Insitute (LGD-NCI) for EBV
immortalisation: 83 per cent of 633 transformation attempts
resulted in LCLs.
Sample and genotyping errors were estimated by including
10 per cent duplicate sampling with one sample derived
from DNA isolated directly from peripheral blood and the
second from DNA isolated from LCLs. Less than 0.5 per cent
mismatches within duplicate samples were observed, all of
which were resolved using family trios, indicating that tubes
collected from a single individual were appropriately labelled
(data not shown) and that error was not introduced during cell
line development or sample handling. A second test for
Mendelian errors using PedChek was performed using the
chromosome 4 microsatellite data (described below). Two
unresolved Mendelian errors were observed within the 366
family triads. Near-complete genotyping and complete clinical
data were available for 350 NPC cases, 288 IgA seropositives
and 346 IgA seronegatives (Table 1).
Phase II enrolment occurred between November 2004 and
July 2005 in Guangxi province. Subjects were enrolled if
at least one parent was from the Guangxi or Guangdong
provinces. NPC cases were identiﬁed as seroincident or
seroprevalent cases presenting at Red Cross hospitals and
IgAþ and IgA2 controls were identiﬁed from ﬁeld stations in
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cities and villages bordering the Xijiang River drainage.
Table 3 presents summary data of environmental exposures
for the Phase II NPCþ, IgAþ and IgA2 groups and the
numbers of participants enrolled.
We have addressed the questions of whether a locus within
the chromosome 4p15.1-q12 region leads to the development
of NPC or the development of EBV/IgA/VCA in response to
EBV replication using the Phase I cases and controls. Microsatellite loci (n ¼ 34) were distributed over an 18 Mb region on
chromosome 4p15.1-q12, with intervals of 10 –3,500 kb and an
average distance of 530 kb. Four Phase I genetic association
comparisons were made: 1) NPC cases versus EBV/IgA/VCA
seropositive controls (Table 4); 2) EBV/IgA/VCA seropositive
cases without NPC versus EBV/IgA/VCA seronegative controls (Table 5); 3) NPC cases plus EBV/IgA/VCA seropositive
cases versus EBV/IgA/VCA seronegative controls (Table 6);
and 4) NPC cases versus EBV/IgA/VCA seronegative controls
(data not shown). No distortions in Hardy-Weinberg equilibrium were observed. Alleles with at least one signiﬁcant result
( p , 0.05) for either the dominant or recessive genetic models
are reported in Tables 4– 6. The results are presented without
correction for multiple comparisons because the interrogated
4p15.1-q12 region was previously implicated as a susceptibility
locus in a family-based study and we were speciﬁcally testing
the prior hypothesis that markers within the region would also
be associated with NPC in a population-based study.32 It should
be noted that associations with p . 0.0015 would not remain
signiﬁcant after correction for multiple comparisons considering the 34 independent loci.

Linkage disequilibrium among the 34 loci

The spacing of markers varied from 10 –3,500 kb, with denser
coverage ﬂanking the microsatellite markers with the highest
LOD scores from the family study (Figure 1). We calculated
two-point D’ as a measure of LD between all alleles at
neighbouring short tandem repeat loci; however, a D’ value of
1 (complete LD) was observed for only 60 two-point allele
combinations. Using HapMap single nucleotide polymorphism (SNP) data (http://www.hapmap.org), we examined
whether the microsatellites were included in reasonably strong
LD blocks. The r2 between any given marker pairs were
set at a 0.8 cut-off threshold to determine the LD blocks.
Only 11 of the 34 microsatellite markers occurred within an
LD block: D4S396 and D4S401 occurred within the same
17 kb block. Of the two NPC-linked markers,32 D4S405
was not within a block and D4S3002 occurred within an
8 kb block. The mean size of the blocks was 17.9 kb
(range 8 – 50 kb).

Genetic association with NPC

Table 4 presents the locus name, location, allele length, allele
frequencies, ORs, p values and 95 per cent CIs for 350
NPC cases and 288 EBV/IgA/VCA seropositive controls

370

(93.0 – 99.7 per cent of NPC cases and 91.0 –97.6 per cent
of IgAþ subjects were genotyped successfully). The genotype
frequencies among NPC cases were signiﬁcantly higher than
those among control subjects for ﬁve alleles (OR 1.51 –5.36;
p ¼ 0.01– 0.03): for the recessive model, D4S3040-215 and
D4S1547-251; and for the dominant model, D4S3040-213,
D4S2974-137 and D4S2916-204. The genotype
frequencies among NPC cases was statistically lower than
among control subjects for four alleles (OR 0.3 –0.71;
p ¼ 0.02– 0.045): for the recessive model, D4S2950-141 and
D4S2974-135; and for the dominant model, D4S3357-271
and D4S2381-277.

Genetic association with persistent IgA1 status

To test the hypothesis that genetic factors may inﬂuence EBV/
IgA/VCA formation in response to EBV infection, we compared genotype frequencies between 288 IgAþ cases and 346
IgA2 controls (Table 1). Table 5 provides the allele frequencies, p values, ORs and 95 per cent CIs in cases and controls
for signiﬁcant results. Eleven alleles were signiﬁcantly associated with IgAþ persistence: ﬁve risk alleles (OR 1.51 –2.38;
p ¼ 0.004 –0.040) and six protective alleles (OR 0.33 – 0.70;
p ¼ 0.002 –0.050).
Because all NPC cases in our study were IgAþ, we then
pooled NPC and IgAþ cases together to increase power, with
the hypothesis being that the alleles associated with IgAþ
serostatus would be shared among NPCþIgAþ and
NPC2IgAþ individuals. Signiﬁcant associations are presented
in Table 6: four alleles were associated with risk for IgAþ (OR
1.5 –1.63; p ¼ 0.001 –0.030) and seven were protective (OR
0.46 – 0.76; p ¼ 0.001– 0.050). Based on the two comparisons
(Tables 5 and 6), ten alleles associated with IgA were shared in
both comparisons. Five were highly signiﬁcant ( p , 0.01)
associations with IgAþ serostatus. Alleles D4S190-170
( p ¼ 0.005; OR 1.5, 95% CI 1.13 – 2.0), D4S3241-136
( p ¼ 0.004; OR 1.91, 95% CI 1.2-3.0) and D4S3347-213
( p ¼ 0.001; OR 1.58, 95% CI 1.2-2.1) signiﬁcantly increased
the risk of developing EBV/IgA/VCA. Alleles D4S174-202
( p ¼ 0.001; OR 0.46, 95% CI 0.3-0.7) and D4S2950-137
( p ¼ 0.0036; OR 0.56, 95 per cent CI 0.38-0.83) signiﬁcantly
decreased the risk of EBV/IgA/VCA. Within a single locus
(D4S3357), one allele increased susceptibility (D4S3357-271)
and the other allele was protective (D4S3357-275).

Discussion
We have described the design and recruitment efforts for a
genetic association study to investigate the role of host genetic
factors in the development of chronic EBV infection
leading to NPC in subjects born and living in a region with
one of the world’s highest incidence rates of NPC. This study
was conducted in two phases. Phase I was a pilot study to
explore the feasibility of conducting a cross-sectional study
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D4S2950

D4S3040

D4S3040

D4S2974

D4S2974

D4S3357

D4S350

D4S1547

D4S2295

D4S2381

D4S2971
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41.57
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43.27
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44.11

44.28
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Allele
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344
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347
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NPC

Individuals #

265

275
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275
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281
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IgA+
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45.1

61.8

76.1

56.4
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29.7
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60.7

15.6

17.4

12.9
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,

.

.

,

.

,

.

.

,

Allele freq (%)

10.6

43.3

65.9

81.3

52.7

58.7

33.4

11.4

64.9

12.5

14.0

19.6

IgA+

1.55

1.43

0.59

0.52

0.91

1.61

0.71

1.51

1.22

1.21

1.52

0.70

OR

Abbreviations: CI, conﬁdence interval; cM, centimorgan; IgA, immunoglobulin A; NPC, nasopharyngeal carcinoma; OR, odds ratio.
* See Figure 1.

Locus

cM*

Table 4. Signiﬁcant allele frequencies between NPC versus IgAþ groups.

0.03

0.05

0.03

0.12

0.64

0.05

0.04

0.03

0.41

0.34

0.03

0.06

p value

Dominant

1.03– 2.33

1.0– 2.05

0.36– 0.95

0.23– 1.19

0.62– 1.35

1.01– 2.56

0.51– 0.99

1.03– 2.20

0.76– 1.97

0.82– 1.79

1.04– 2.22

0.48– 1.01

95% CI

0.57

0.76

0.92

0.71

1.53

1.24

1.01

3.43

0.67

5.36

1.47

0.30

OR

0.39

0.20

0.60

0.05

0.02

0.21

0.98

0.07

0.02

0.03

0.42

0.02

p value

Recessive

0.16– 2.07

0.50– 1.1

0.66– 1.28

0.50– 1.0

1.07– 2.19

0.89– 1.7

0.60– 1.71

0.92– 12.85

0.48– 0.93

1.17– 24.53

0.57– 3.75

0.11– 0.84

95% CI
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D4S2950

D4S190

D4S174

D4S3357

D4S1627

D4S3241

D4S2381

D4S1536

D4S1577

D4S3347

D4S3347

D4S1594
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40.14

40.75

43.27
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44.48
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202
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137

Allele

236

237

237

238
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238

233
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IgA+

Individuals #

330
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332

332
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335
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332
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IgA 2

66.1

45.4

34.8

34.2

33.7
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33.3

34.3

23.4

23.9

13.3

IgA+

.

,

.

,

,

,

.

,

.

,

.

,

64.2

50.0

29.5

41.6

40.7

23.0

8.9

38.1

27.8

32.6

18.7

18.5

IgA 2

Allele freq (%)

Abbreviations: CI, conﬁdence interval; cM, centimorgan; IgA, immunoglobulin A; OR, odds ratio.

Locus

cM

1.76

0.87

1.65

0.70

0.79

0.70

1.91

0.81

1.51

0.59

1.40

0.56

OR

0.04

0.48

0.004

0.05

0.19

0.05

0.004

0.24

0.02

0.003

0.06

0.004

p value

Dominant

1.02 – 3.03

0.59 – 1.28

1.17 – 2.33

0.49 – 1.0

0.56 – 1.13

0.49 – 1.0

1.24 – 2.94

0.58 – 1.15

1.06 – 2.13

0.42 – 0.84

0.98 – 1.99

0.38 – 0.83

95% CI

Table 5. Group 2: Markers and alleles showing signiﬁcant allele frequencies among IgAþ cases without NPC and IgA2 subjects.

1.01

0.66

0.89

0.52

0.48

0.90

2.11

0.57

1.46

0.33

2.38

0.75

OR

0.95

0.05

0.67

0.01

0.01

0.80

0.28

0.039

0.20

0.002

0.04

0.56

p value

Recessive

0.71 – 1.43

0.43 – 1.0

0.50 – 1.56

0.31 – 0.86

0.27 – 0.84

0.42

0.54 – 8.27

0.33 – 0.97

0.82 – 2.61

0.16 – 0.67

1.03 – 5.49

0.28 – 2.00

95% CI
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136
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Abbreviations: CI, conﬁdence interval; cM, centimorgan; IgA, immunoglobulin A; OR, odds ratio.

Locus

cM

64.2

50.0

29.5

41.6

6.1

11.1

40.7

8.9

38.1

24.8

8.5

32.6

18.7

18.5

IgA2

1.57

0.90

1.58

0.72

1.50

1.09

0.78

1.63

0.76

0.72

1.45

0.79

1.50

0.69

OR

0.03

0.48

0.001

0.02

0.05

0.63

0.09

0.007

0.05

0.02

0.04

0.10

0.005

0.01

p value

Dominant

1.04– 2.38

0.66– 1.22

1.20– 2.08

0.54– 0.95

1.0– 2.25

0.77– 1.53

0.59– 1.04

1.14– 2.31

0.58– 1.0

0.55– 0.96

1.02– 2.08

0.60– 1.05

1.13– 1.99

0.51– 0.93

95% CI

Table 6. Group 3: Markers and alleles showing signiﬁcant allele frequencies among NPC cases plus IgAþ cases and IgA2 subjects.

1.03

0.62

1.02

0.67

3.18

0.33

0.55

1.85

0.57

0.95

3.17

0.46

1.99

1.06

OR

0.86

0.004

0.93

0.03

0.30

0.05

0.004

0.30

0.007

0.87

0.15

0.001

0.07

0.88

p value

Recessive

0.78 – 1.35

0.45 – 0.86

0.66 – 1.58

0.46 – 0.96

0.36 – 28.0

0.11 – 1.00

0.37 – 0.83

0.58 – 5.89

0.38 – 0.86

0.51 – 1.75

0.67 – 15.0

0.28 – 0.74

0.96 – 4.14

0.50 – 2.26

95% CI
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in China (Table 1). The pilot provided strong support for
expanding the study in several important ways: export permits
for genetic material were obtained, sample handling was
excellent — with few detectable errors — and recruitment
goals were attainable. Upon the successful completion of Phase
I, we increased the catchment area for IgAþ cases to cities
and villages along the Xijiang River and tributaries, expanded
the study to include more subjects and added a detailed
questionnaire to capture environmental exposures that may
interact with host genes in the development of NPC (Table 2).
Complementing previous studies, we also attempted to determine if Phase II of the study was powered for the detection
of both gene–gene and gene–environment interactions.
To revisit the recent linkage analysis in NPC families
implicating a susceptibility locus linked to chromosome
4p15.1-q12, we selected 34 microsatellite loci spanning the
18 Mb region at intervals of 10 –3,500 kb. Unlike in previous
studies, we ﬁrst also attempted to determine if the chromosome 4 region was associated with EBV/IgA/VCA antibody
formation and, secondly, if the chromosome 4 region was
associated with NPC incidence in the setting of EBV replication as indicated by EBV/IgA/VCA. We identiﬁed several
loci that showed signiﬁcant associations with either EBV/IgA/
VCA or NPC status. The associations tended to be marginally
signiﬁcant for NPC (Table 4), with somewhat stronger
associations observed for EBV/IgA/VCA (IgAþ)
(Tables 5 and 6).
Few NPC families have been identiﬁed outside of NPC
endemic areas. More than 90 per cent of all NPC cases do not
show familial aggregation or family history, implying either
environmental causes or geographical family clustering. Two
family-based NPC linkage studies implicated different
chromosomes as harbouring an NPC susceptibility locus.32,33
Although the studies differed in strategy, both used multiple
families with two or more NPC cases from two separate high
NPC incident provinces in China and included similar numbers of families and affected cases. Although it is possible
that environmental exposures may differ between the two
provinces, it is unlikely that different environmental factors
account for the lack of concordance between the studies.
More likely, multiple genes predispose to chronic EBV replication and the development of NPC, each of which may
contribute only a small part of the total genetic inﬂuence.
Family-based linkage studies are ideal for identifying single
genes with large effects, but are relatively insensitive for
localising genetic factors with small effects. By contrast, casecontrol association studies are ideal for identifying genetic
factors with small or moderate effects once a candidate gene or
region has been identiﬁed.38
We cannot exclude the possibility that there may be causal
alleles in the chromosome 4 region that may be associated
with chronic EBV replication or a predisposition to develop
NPC. Marker associations within this region (Tables 4 –6) may
be tracking a susceptible locus through LD. Because included
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alleles predominantly occurred at very low frequencies and
haplotype inferences were unreliable, we could not reliably
assess associations with either EBV persistence or NPC (data
not shown). A denser placement of polymorphic markers is
required to survey the genetic variation content of the region
more thoroughly.
Although this study did not ﬁnd associations with robust p
values for NPC, making conclusions tentative, a number of loci
did show moderate to strong risk, suggesting that this region
warrants further attention, particularly for chronic EBV replication. For one of the microsatelite loci D4s3347 (Tables 5
and 6), two alleles were associated with EBV/IgA/VCA,
suggesting that these alleles may be tracking a potential causative
allele (see Figure 1). Of potential interest is the association of
two microsatellites with IgA incidence: D4S3347, which
shows three signiﬁcant associations with p , 0.01 and one
with p , 0.05 for two alleles (213 and 217), and the tightly
linked (, 20 kb) D4S1577 locus, which also shows four signiﬁcant associations ( p , 0.05) (Tables 5 and 6, Figure 1).
Microsatellite D4S190 occurs within the oncogene ARHH.
D4S190 was associated with risk for EBV/IgA/VCA seropositive status but not with NPC. ARHH, a member of the ras
homolog gene family, encodes a small GTP-binding protein
belonging to the RAS superfamily and is transcribed by only
haemopoietic cells. ARHH non-coding variants that may affect
expression are observed in 46 per cent of diffuse large-cell
lymphomas.39 It is possible that one or more variant alleles
of ARHH in LD with associated D4S190-170 may modify
EBV replication.
Given the similar geographical distribution of familial and
non-familial NPC, it is likely that both forms share similar
aetiological risk factors, particularly environmental and viral
factors; however, it is likely that the genetic factors underpinning familial, early-onset and non-familial NPC susceptibility may also overlap. It is also possible that different genes
contribute to familial NPC cases, analogous to the situation in
breast cancer, where BRCA1 and BRCA2 account for only
a small proportion of non-familial breast cancer cases.40,41
The best approach to identifying NPC susceptibility factors
may be the organisation of well-designed and highly powered
case–control studies for whole-genome and targeted candidate
gene association investigations, as we describe here.
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